Loading...
•
Sep 30, 2020
Allovir Q3 2020 Earnings Report
Reported financial results for the third quarter of 2020.
Key Takeaways
AlloVir completed its initial public offering, raising $317.7 million in gross proceeds, and is focused on executing its pipeline objectives, including commencing pivotal and proof-of-concept studies across three cell therapies.
Completed initial public offering raising $317.7M in gross proceeds.
Viralym-M registrational study in virus-associated hemorrhagic cystitis and proof-of-concept study in prevention of multiple viral infections on track to initiate before year end.
ALVR109 Phase 1/2 clinical trial initiated for the treatment of high risk COVID-19 patients.
Commenced tech transfer for AlloVir proprietary virus-specific T-cell manufacturing process to ElevateBio BaseCamp, as part of planned manufacturing capacity expansion and redundancy within supply chain.
Forward Guidance
AlloVir expects its current cash and cash equivalents, inclusive of IPO net proceeds, will be sufficient to fund its current operating plan into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...